Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

Creative Medical Technology Holdings (CELZ) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Creative Medical Technology Holdings (CELZ) over the last 17 years, with Q3 2025 value amounting to $1.3 million.

  • Creative Medical Technology Holdings' Operating Expenses rose 1472.14% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 798.0%. This contributed to the annual value of $5.8 million for FY2024, which is 222.07% up from last year.
  • Creative Medical Technology Holdings' Operating Expenses amounted to $1.3 million in Q3 2025, which was up 1472.14% from $1.3 million recorded in Q2 2025.
  • Creative Medical Technology Holdings' Operating Expenses' 5-year high stood at $6.3 million during Q4 2022, with a 5-year trough of $303944.0 in Q1 2021.
  • Its 5-year average for Operating Expenses is $1.5 million, with a median of $1.3 million in 2025.
  • In the last 5 years, Creative Medical Technology Holdings' Operating Expenses soared by 35135.13% in 2021 and then tumbled by 7180.6% in 2023.
  • Over the past 5 years, Creative Medical Technology Holdings' Operating Expenses (Quarter) stood at $1.5 million in 2021, then surged by 319.1% to $6.3 million in 2022, then crashed by 71.81% to $1.8 million in 2023, then increased by 6.42% to $1.9 million in 2024, then plummeted by 32.56% to $1.3 million in 2025.
  • Its Operating Expenses stands at $1.3 million for Q3 2025, versus $1.3 million for Q2 2025 and $1.7 million for Q1 2025.